Table 3.

Select trials of EGFR-targeting agents as part of chemoradiotherapy

^aThis data represents one arm of a randomized phase II trials. The first 19 patients on trial received carboplatin (AUC = 6).

^bNumbers represent patients randomized to gefitinib or placebo after completion of cisplatin/etoposide and concurrent thoracic radiation therapy and docetaxel.

^cPoor risk was defined as ≥5% weight loss and/or performance status of 2. Good risk was defined as weight loss <5% and performance status of 0–1.

Abbreviation: AUC: area under the curve.